S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
The Battery Metal Nobody Told You About (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
The Battery Metal Nobody Told You About (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

CASI Pharmaceuticals (CASI) Competitors

$5.96
+0.04 (+0.68%)
(As of 12/5/2023 ET)
Compare
Today's Range
$5.63
$5.98
50-Day Range
$2.30
$5.96
52-Week Range
$1.45
$5.98
Volume
42,135 shs
Average Volume
31,674 shs
Market Capitalization
$79.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

CASI vs. NKGN, ATRA, CDTX, SGMO, IKNA, CRIS, TSBX, CRDL, JSPR, and LIFE

Should you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include NKGen Biotech (NKGN), Atara Biotherapeutics (ATRA), Cidara Therapeutics (CDTX), Sangamo Therapeutics (SGMO), Ikena Oncology (IKNA), Curis (CRIS), Turnstone Biologics (TSBX), Cardiol Therapeutics (CRDL), Jasper Therapeutics (JSPR), and aTyr Pharma (LIFE). These companies are all part of the "biological products, except diagnostic" industry.

CASI Pharmaceuticals vs.

NKGen Biotech (NYSE:NKGN) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, NKGen Biotech had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.50 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Positive
CASI Pharmaceuticals Positive

NKGen Biotech has higher earnings, but lower revenue than CASI Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A$4.55MN/AN/A
CASI Pharmaceuticals$43.11M1.84-$41.01M-$3.01-1.98

CASI Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 101.34%. Given NKGen Biotech's higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
CASI Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NKGen Biotech has a net margin of 0.00% compared to NKGen Biotech's net margin of -95.24%. CASI Pharmaceuticals' return on equity of -2.50% beat NKGen Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A -2.50% -24.01%
CASI Pharmaceuticals -95.24%-110.90%-47.81%

28.5% of NKGen Biotech shares are owned by institutional investors. Comparatively, 14.6% of CASI Pharmaceuticals shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CASI Pharmaceuticals received 199 more outperform votes than NKGen Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
NKGen BiotechN/AN/A
CASI PharmaceuticalsOutperform Votes
199
53.93%
Underperform Votes
170
46.07%

Summary

NKGen Biotech beats CASI Pharmaceuticals on 6 of the 11 factors compared between the two stocks.


Get CASI Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CASI vs. The Competition

MetricCASI PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$79.39M$2.48B$4.37B$6.66B
Dividend YieldN/A2.33%5.51%4.79%
P/E Ratio-1.986.84130.2014.11
Price / Sales1.84177.473,094.87284.08
Price / CashN/A28.3021.5623.12
Price / Book1.823.353.934.62
Net Income-$41.01M$54.56M$121.41M$176.69M
7 Day Performance16.18%3.06%3.09%2.34%
1 Month Performance38.60%2.41%6.35%6.17%
1 Year Performance227.47%9.79%9.11%6.29%

CASI Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
0 of 5 stars
$2.98
+3.5%
N/AN/A$65.23MN/A0.00N/AGap Up
ATRA
Atara Biotherapeutics
2.7721 of 5 stars
$0.61
-3.2%
$28.00
+4,485.7%
-86.4%$62.23M$63.57M-0.22334
CDTX
Cidara Therapeutics
2.3191 of 5 stars
$0.68
-2.8%
$4.67
+584.3%
+30.0%$61.67M$64.29M-1.7573Positive News
SGMO
Sangamo Therapeutics
1.9057 of 5 stars
$0.39
+5.4%
$4.68
+1,093.5%
-87.3%$69.47M$111.30M-0.27478Analyst Report
IKNA
Ikena Oncology
2.3056 of 5 stars
$1.44
-10.6%
$11.67
+710.2%
-32.7%$69.49M$15.62M-0.8957Positive News
CRIS
Curis
1.8735 of 5 stars
$11.97
+9.8%
$68.67
+473.7%
-30.6%$70.38M$10.16M-1.2851News Coverage
High Trading Volume
TSBX
Turnstone Biologics
1.5486 of 5 stars
$2.52
-2.7%
$19.00
+654.0%
N/A$58.19M$73.30M0.0094
CRDL
Cardiol Therapeutics
2.0309 of 5 stars
$0.89
flat
$3.00
+235.5%
+89.0%$58.14M$60,000.00-2.71N/APositive News
JSPR
Jasper Therapeutics
2.246 of 5 stars
$0.65
flat
$5.96
+817.4%
+1.8%$72.51MN/A-0.7835Gap Up
LIFE
aTyr Pharma
2.4661 of 5 stars
$1.25
-1.6%
$20.75
+1,560.0%
-45.4%$73.20M$10.39M-1.2965Positive News

Related Companies and Tools

This page (NASDAQ:CASI) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -